Welcome to our dedicated page for MYND LIFE SCIENCS news (Ticker: MYNDF), a resource for investors and traders seeking the latest updates and insights on MYND LIFE SCIENCS stock.
MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuropharmaceutical and novel drug development, diagnostics, and vaccines. MYND is dedicated to commercializing proprietary biomarker diagnostic tests and novel therapeutics for patients battling with Major Depressive Disorder (MDD), Treatment-Resistant Depression (TRD), and other neuro-inflammatory disorders. The company is currently in discussions regarding its unsecured convertible debentures and has formed a special committee to evaluate alternatives. Moreover, MYND has recently announced a potential merger with Cava Healthcare Inc, aiming to create a powerful new commercial entity by combining their patents and expertise to revolutionize treatments for neurological and inflammatory diseases.
MYND Diagnostics has announced its involvement in a $3 million clinical trial funded by the Government of Australia, aimed at evaluating psilocybin-assisted psychotherapy for treatment-resistant depression. The trial will employ MYND's proprietary biomarkers to monitor patient responses and progress. Conducted by Dr. Paul Fitzgerald at Monash University, this phase 2b trial could lead to a multi-site phase 3 trial within a year, paving the way for potential regulatory approval by the Therapeutic Goods Association. MYND also anticipates entering more clinical trials in 2022/2023 to advance its biomarker development.
MYND Life Sciences Inc. has entered a Collaborative Research Agreement with the University of British Columbia to explore novel therapies for neurological diseases. The focus is on developing precision medicines, particularly those involving Psilocybins, aimed at improving treatment outcomes for conditions like dementia.
MYND is advancing various clinical programs, including a pivotal trial for novel biomarkers for treatment-resistant depression, with plans for additional clinical trials in 2022/2023. The company also announced the departure of COO Jordan Cleland, with Dr. Chahaat Singh assuming operational responsibilities.
MYND Life Sciences has completed the acquisition of intellectual property rights to use psychedelics for treating dementia, including Alzheimer's disease, from Cava Healthcare. This acquisition is expected to enhance MYND's capabilities in psilocybin-assisted therapy, which is aimed at addressing a condition that affects 44 to 50 million people globally. MYND issued 450,000 shares at $0.85 each and made a cash payment of $120,000. An annual royalty of $240,000 or 4% of net sales will also be paid. The acquisition positions MYND as a leader in psychedelic therapeutics for dementia.
MYND Life Sciences Inc. (CSE: MYND, OTC: MYNDF) announced the completion of its National Phase filing for a Patent Cooperation Treaty (PCT) application related to a method of immune modulation targeting a specific gene. CEO Dr. Lyle Oberg stated that building a solid intellectual property portfolio is crucial for long-term shareholder value. The PCT enables simultaneous patent protection across multiple countries. MYND aims to advance its drug pipeline to file for Innovative New Drug (IND) application. The company has also engaged Hybrid Financial Ltd. for marketing services.
FAQ
What is the current stock price of MYND LIFE SCIENCS (MYNDF)?
What is the market cap of MYND LIFE SCIENCS (MYNDF)?
What is MYND Life Sciences Inc. focused on?
Which disorders does MYND target with its therapeutics?
What recent announcement did MYND make about its convertible debentures?
What is the purpose of the special committee formed by MYND?
What potential merger has MYND announced recently?